Savara Inc
SVRA2.565USD
-0.025-0.97%
Horário de mercado （ET）Cotações atrasadas em 15 min
442.98MValor de mercado
PerdaP/L TTM
Mais detalhes de Savara Inc Empresa
Savara Inc. is a clinical-stage biopharmaceutical company, which is focused on rare respiratory diseases. The Company’s lead program, molgramostim nebulizer solution (molgramostim), is an inhaled biologic, specifically an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase III development for autoimmune pulmonary alveolar proteinosis (aPAP). Molgramostim is an inhaled formulation of recombinant human GM-CSF and is being developed for the treatment of aPAP. Molgramostim nebulizer solution is administered once daily by inhalation via a high efficiency nebulizer, the eFlow Nebulizer System (PARI Pharma GmbH). Pulmonary alveolar proteinosis (PAP) is a rare lung disease characterized by the accumulation of surfactant in the alveoli (or air sacs) of the lungs. The Company is engaged in the advancement of the molgramostim aPAP program and the Phase III IMPALA-2 clinical trial and outsourcing capital-intensive operations.
Informações da empresa
Código da empresaSVRA
Nome da EmpresaSavara Inc
Data de listagemJun 25, 2001
CEOMr. Matthew (Matt) Pauls, J.D.
Número de funcionários59
Tipo de títulosOrdinary Share
Fim do ano fiscalJun 25
Endereço6836 Bee Cave Road
CidadeAUSTIN
Bolsa de valoresNASDAQ Global Select Consolidated
PaísUnited States of America
Código postal78746
Telefone151285113796
Sitehttps://savarapharma.com/
Código da empresaSVRA
Data de listagemJun 25, 2001
CEOMr. Matthew (Matt) Pauls, J.D.
Executivos da empresa
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. David A. Ramsay
Mr. David A. Ramsay
Independent Director
Independent Director
2.47M
-0.70%
Dr. Joseph S. (Joe) Mccracken, Ph.D.
Dr. Joseph S. (Joe) Mccracken, Ph.D.
Lead Independent Director
Lead Independent Director
220.84K
+4.74%
Ms. Anne Erickson
Ms. Anne Erickson
Chief Business Officer
Chief Business Officer
194.99K
+72.18%
Mr. Braden Parker
Mr. Braden Parker
Chief Commercial Officer
Chief Commercial Officer
105.00K
+23.53%
Mr. Robert Matthew (Rob) Lutz
Mr. Robert Matthew (Rob) Lutz
Chief Operating Officer
Chief Operating Officer
101.74K
+64.79%
Mr. Nevan Charles Elam, J.D.
Mr. Nevan Charles Elam, J.D.
Independent Director
Independent Director
--
--
Mr. Richard J. (Rick) Hawkins
Mr. Richard J. (Rick) Hawkins
Independent Director
Independent Director
--
--
Mr. David L. Lowrance, CPA
Mr. David L. Lowrance, CPA
Chief Financial and Administrative Officer, Secretary
Chief Financial and Administrative Officer, Secretary
--
--
Mr. Matthew (Matt) Pauls, J.D.
Mr. Matthew (Matt) Pauls, J.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
--
--
Dr. Raymond Dennis (Ray) Pratt, M.D.
Dr. Raymond Dennis (Ray) Pratt, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. David A. Ramsay
Mr. David A. Ramsay
Independent Director
Independent Director
2.47M
-0.70%
Dr. Joseph S. (Joe) Mccracken, Ph.D.
Dr. Joseph S. (Joe) Mccracken, Ph.D.
Lead Independent Director
Lead Independent Director
220.84K
+4.74%
Ms. Anne Erickson
Ms. Anne Erickson
Chief Business Officer
Chief Business Officer
194.99K
+72.18%
Mr. Braden Parker
Mr. Braden Parker
Chief Commercial Officer
Chief Commercial Officer
105.00K
+23.53%
Mr. Robert Matthew (Rob) Lutz
Mr. Robert Matthew (Rob) Lutz
Chief Operating Officer
Chief Operating Officer
101.74K
+64.79%
Mr. Nevan Charles Elam, J.D.
Mr. Nevan Charles Elam, J.D.
Independent Director
Independent Director
--
--
Detalhamento da receita
Sem dados
Sem dados
Por Empresa
Por Região
Sem dados
Distribuição de ações
Atualizado em: sex, 16 de mai
Atualizado em: sex, 16 de mai
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
New Enterprise Associates (NEA)
14.16%
Bain Capital Life Sciences Investors, LLC
10.18%
TCG Crossover Management, LLC
7.15%
Frazier Life Sciences Management, L.P.
6.63%
Vestal Point Capital, LP
6.36%
Other
55.51%
Investidores
Investidores
Proporção
New Enterprise Associates (NEA)
14.16%
Bain Capital Life Sciences Investors, LLC
10.18%
TCG Crossover Management, LLC
7.15%
Frazier Life Sciences Management, L.P.
6.63%
Vestal Point Capital, LP
6.36%
Other
55.51%
Tipos de investidores
Investidores
Proporção
Investment Advisor
33.05%
Venture Capital
22.55%
Hedge Fund
19.34%
Investment Advisor/Hedge Fund
16.33%
Private Equity
6.63%
Corporation
2.71%
Individual Investor
2.67%
Research Firm
1.67%
Bank and Trust
0.25%
Participação acionária institucional
Atualizado em: ter, 1 de jul
Atualizado em: ter, 1 de jul
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q2
294
182.03M
105.32%
-6.77M
2025Q1
306
176.74M
102.29%
-9.64M
2024Q4
294
173.80M
101.27%
-5.45M
2024Q3
274
169.68M
103.28%
+3.87M
2024Q2
257
157.29M
95.89%
+28.15M
2024Q1
230
131.01M
94.21%
-92.17K
2023Q4
197
123.19M
91.03%
-2.15M
2023Q3
177
120.11M
89.27%
+14.67M
2023Q2
170
92.45M
81.05%
-2.68M
2023Q1
166
87.31M
76.55%
-5.82M
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
New Enterprise Associates (NEA)
24.47M
14.16%
--
--
Mar 31, 2025
Bain Capital Life Sciences Investors, LLC
17.60M
10.18%
+3.04M
+20.84%
Mar 31, 2025
TCG Crossover Management, LLC
12.36M
7.15%
--
--
Mar 31, 2025
Frazier Life Sciences Management, L.P.
11.46M
6.63%
+2.80M
+32.35%
Mar 31, 2025
Vestal Point Capital, LP
11.00M
6.36%
+225.00K
+2.09%
Mar 31, 2025
VR Adviser, LLC
3.26M
1.88%
+3.26M
--
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
8.71M
5.04%
+229.91K
+2.71%
Mar 31, 2025
The Vanguard Group, Inc.
8.10M
4.69%
-190.72K
-2.30%
Mar 31, 2025
Nantahala Capital Management, LLC
8.08M
4.67%
+550.12K
+7.31%
Mar 31, 2025
Deerfield Management Company, L.P.
7.96M
4.61%
--
--
Mar 31, 2025
Ver Mais
ETFs Relacionados
Atualizado em: sáb, 2 de ago
Atualizado em: sáb, 2 de ago
Nome
Proporção
Virtus LifeSci Biotech Clinical Trials ETF
0.91%
Texas Capital Texas Small Cap Equity Index ETF
0.39%
iShares Micro-Cap ETF
0.07%
Texas Capital Texas Equity Index ETF
0.04%
Invesco Nasdaq Biotechnology ETF
0.04%
ProShares Ultra Nasdaq Biotechnology
0.04%
iShares ESG Aware MSCI USA Small-Cap ETF
0.04%
Nuveen ESG Small-Cap ETF
0.02%
iShares Russell 2000 Growth ETF
0.02%
iShares Biotechnology ETF
0.02%
Ver Mais
Virtus LifeSci Biotech Clinical Trials ETF
Proporção0.91%
Texas Capital Texas Small Cap Equity Index ETF
Proporção0.39%
iShares Micro-Cap ETF
Proporção0.07%
Texas Capital Texas Equity Index ETF
Proporção0.04%
Invesco Nasdaq Biotechnology ETF
Proporção0.04%
ProShares Ultra Nasdaq Biotechnology
Proporção0.04%
iShares ESG Aware MSCI USA Small-Cap ETF
Proporção0.04%
Nuveen ESG Small-Cap ETF
Proporção0.02%
iShares Russell 2000 Growth ETF
Proporção0.02%
iShares Biotechnology ETF
Proporção0.02%
Dividendo
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Tipo
Proporção
Sem dados
Data
Tipo
Proporção
Sem dados
